Recombinant Osteoprotegerin Protein, Human (His Tag) Others The human TNFRSF11B (NP_002537.3) (Met 1-Leu 401) was fused with a polyhistidine tag at the C-terminus The secreted recombinant human TNFRSF11B comprises 391a.a and has a predicted molecular weight of 45.3 kDa. As a result of glycosylation, rhTNFRSF11B migrates as an approximately 55 kDa bnd in SDS-PAGE under reducing conditions.
$ $99 In stock
Formulation: The secreted recombinant human TNFRSF11B comprises 391a.a and has a predicted molecular weight of 45.3 kDa. As a result of glycosylation, rhTNFRSF11B migrates as an approximately 55 kDa bnd in SDS-PAGE under reducing conditions.
Source: HEK293 Cells
Usage: Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use
Recombinant Osteoprotegerin Protein, Human (His Tag) -

Recombinant Osteoprotegerin Protein, Human (His Tag)

The product is for non-human research only. Not for therapeutic or veterinary use.

Catalog Number: BT-201315

Molecular Weight: The secreted recombinant human TNFRSF11B comprises 391a.a and has a predicted molecular weight of 45.3 kDa. As a result of glycosylation, rhTNFRSF11B migrates as an approximately 55 kDa bnd in SDS-PAGE under reducing conditions.

Formulation: Recombinant Osteoprotegerin Protein was lyophilized from sterile PBS, pH 7.41

Source: HEK293 Cells

Product Name Recombinant Osteoprotegerin Protein, Human (His Tag)
Molecular Weight The secreted recombinant human TNFRSF11B comprises 391a.a and has a predicted molecular weight of 45.3 kDa. As a result of glycosylation, rhTNFRSF11B migrates as an approximately 55 kDa bnd in SDS-PAGE under reducing conditions.
AA Sequence Met 1-Leu 401
Bioactivity 1. Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is typically 5-20 ng/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10 (Catalog # 10409-HNAE).2. Measured by its binding ability in a functional ELISA. Immobilized human TNFRSF11B-His at 10 ug/ml (100 ul/well) can bind human Fc-TNFSF11 (Cat:11682-H01H) with a linear ranger of 3.125-200 ng/mL.
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Formulation Recombinant Osteoprotegerin Protein was lyophilized from sterile PBS, pH 7.41
Host Species Homo sapiens (Human)
Description The human TNFRSF11B (NP_002537.3) (Met 1-Leu 401) was fused with a polyhistidine tag at the C-terminus
Product Background Osteoprotegerin or TNFRSF11B is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. Osteoprotegerin/TNFRSF11B acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. This protein may inhibit the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. Osteoprotegerin/TNFRSF11B also play a role in preventing arterial calcification, act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
Product Memo MGC29565 Protein, Human;OCIF Protein, Human;OPG Protein, Human;PDB5 Protein, Human;TR1 Protein, Human
Product Type Recombinant Protein
Source HEK293 Cells
Storage Store recombinant protein under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Terminal Glu 22
Usage Our products are for research use only. This product is not intended or approved for human, diagnostics or veterinary use
Last Modified Jul 26 2021